Skip to main content

Table 4 Recurrence rate and median recurrence-free survival (RFS) for Keyhole Limpet Hemocyanin (KLH) and mitomycin C (MM) for group 1 and group 2

From: Quality of transurethral resection of bladder tumor procedure influenced a phase III trial comparing the effect of KLH and mitomycin C

Treatment received

Hospital groupa

Recurrence rate (%)

Median (weeks)

95% confidence interval

Lower bound

Upper bound

KLH

Group 1

74

84

64

103

Group 2

54

139

100

178

Mitomycin C

Group 1

26

N/Ab

N/Ab

N/Ab

Group 2

39

297

152

442

  1. aGroup 1 = 6 hospitals, Group 2 = 12 hospitals
  2. bNot attainable